Ovarian Cancer

A novel antibody drug conjugate was granted a Fast Track designation for certain patients with ovarian cancer.

As Anna “Chickadee” Cardwell from “Here Comes Honey Boo Boo” dies from cancer and former tennis player Chris Evert announces cancer diagnosis, here is what’s happening in the oncology space this week.

The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

IRON, an artificial intelligence model, has an 80% accuracy rate of predicting therapy outcomes of patients with ovarian cancer.

A multidisciplinary surgical approach decreased death rates by 70% in patients with ovarian cancer.

From Suzanne Somers’ death from metastatic breast cancer and Julia Louis-Dreyfus discusses her outlook on life post-diagnosis, here is what’s happening in the oncology space this week.

Treatment with Tecentriq plus Zejula and chemotherapy did not offer better outcomes to patients with recurrent ovarian cancer, according to results from a phase 3 trial.

The phase 3 FLAMES trial showed a benefit of progression-free survival with senaparib compared to placebo in patients with newly diagnosed, advanced ovarian cancer.

The overexpression of the gene, BRD4, may be the cause of chemotherapy resistance in patients with high-grade serous ovarian cancer, according to research.

Interim results of a trial displayed promising results for patients with ovarian cancer treated with IMNN-01 with neoadjuvant chemotherapy and a PARP inhibitor.

As Teddi Mellencamp reveals more about her cancer diagnosis and Shannen Doherty receives a standing ovation after her stage 4 cancer diagnosis, here’s what is happening in the oncology space this week.

Recent developments in PARP inhibitor combinations and antibody-drug-conjugates are changing the landscape of ovarian cancer treatment.

Exercise was shown to reduce chemotherapy-induced peripheral neuropathy in ovarian cancer survivors, according to findings from a recent study.

High-level results from a phase 3 trial demonstrated that treatment with batiraxcept did not improve progression-free survival in patients with platinum-resistant ovarian cancer.

As Ben Alldis reveals previous cancer diagnosis and Luke Combs brings a Make-a-Wish cancer survivor on stage during a concert venue, this is what’s occurring in the oncology space this week.

Sometimes difficult experiences like cancer can come with blessings in disguise.

Frontline Zejula maintenance therapy decreased the risk of disease progression or death in patients with newly diagnosed ovarian cancer.

Patients with advanced ovarian cancer who achieved complete cytoreduction had the best outcomes, regardless of the number of chemotherapy cycles before surgery.

The final overall survival results of the PAOLA-1/ENGOT-ov25 trial confirmed the drug combination as “one of the standards of care” for some populations of patients with ovarian cancer.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Patients with platinum-resistant or refractory ovarian cancer experienced deep responses and survival benefits in a trial assessing immunotherapy with chemotherapy.

Meaningful improvements in survival were obtained with Zejula maintenance therapy compared with placebo in patients with advanced ovarian cancer that was newly diagnosed.

A progression-free survival benefit was observed in patients with advanced ovarian cancer including those with homologous recombination deficient-positive status who were treated with frontline chemo plus Avastin and Imfinzi followed by maintenance therapy with an Avastin regimen.

As more personalized treatments become available in the ovarian cancer space, tumor testing, such as next-generation sequencing, may play a bigger role.